Baaritaanka kansarka xubinta taranka dumarka
Is it safe to extend the screening interval to 5 years or more after a negative screening result? A new study shows that the risk of cervical cancer after one or more combined HPV tests and cytology screening results is negative Is significantly reduced. The study found a follow-up analysis of 1 million female subjects. The analysis showed that the risk of invasive kansarka ilma-mareenka and cervical CIN3 lesions decreased with each round of combined testing and screening. This risk reduction is most significant between the first and second rounds, and is more significant than the second and third rounds. (Ann Intern Med. November 27, 2017 online version)
Tilmaamaha baaritaanka kansarka ilmo-galeenka ayaa isbedelay, gaar ahaan tallaalka HPV. Daabacaadda 2015 ee tilmaamaha ACOG waxay ku talinaysaa in baadhista HPV loo isticmaali karo hab kale oo baadhis ah oo loogu talagalay haweenka ka weyn 25 sano. Waxaa lagu talinayaa in la helo cytology 3dii sanaba mar. Waxa kale oo la tilmaamay in isku-darka cytology iyo baaritaanka HPV ay aad u doorbidaan. Tilmaanta qabyada ah ee USPSTF waxay ku talinaysaa in la tijaabiyo kaliya noocyada hoosaadka khatarta sare leh ee HPV. Beddelka cytology fudud ee haweenka ka weyn 30, baaritaanka wadajirka ah laguma talinayo.
Baarayaasha ayaa tilmaamay in aysan jirin cadeymo badan oo cilmi baaris ah oo ku saabsan waxtarka baaritaanka HPV, inta badanna daraasadaha baaritaanka HPV ee la daabacay waxay ku saleysan yihiin wareega baaritaanka. Cilmi baarayaashu waxay falanqeeyeen 990013 haween ah oo baaritaan wadajir ah lagu sameeyay sanadihii 2003 ilaa 2014, waxayna falanqeeyeen isbedelka halista kansarka xubinta taranka dumarka kadib markii natiijooyinka tijaabada wadajirka ah ee wadajirka ah ay ahaayeen kuwa xun.
Falanqaynta ayaa lagu ogaaday in natiijada xun ee baaritaanka la isku daray ay korodhay, khatarta kansarka ilmo-galeenka iyo ≥CIN3 nabarrada ayaa sii waday inay hoos u dhacdo, iyo saameynta xun ee baaritaanka ugu horreeya ee la isku daray ayaa saameyn weyn ku yeeshay dhimista khatarta. Wareeg kasta oo baadhis ah, saamaynta natiijooyinka baaritaanka HPV ee saafiga ah ee halista kansarka waa mid joogto ah, iyadoon loo eegin natiijooyinka baaritaanka cytological, iyadoon loo eegin natiijooyinka baaritaanka la isku daray. Kuwa diidmada ah ee baadhistii ugu horreysay ee HPV waxay 5-sano hoos u dhigeen khatarta kansarka ilmo galeenka ee 0.0092%, iyo kuwa natiijada baaritaanka saddexaad ee taban waxay hoos u dhigtay 0.0015% khatarta; Khatarta 3-sano ee kansarka afka ilmo-galeenka ayaa ah mid taban baaritaannada koowaad iyo saddexaad Hoos u dhaca 0.0081% iyo 0.0015%. Saddexdii sano ee khatarta cytological taban ee kansarka waxaa la dhimay 0.0140% iyo 0.0023%, siday u kala horreeyaan.
Cilmi-baare ayaa faallo ka bixiyay in daraasadda ay muujisay in tijaabadii ugu horreysay ee wadajirka ah, haweenka leh baaritaannada HPV ee aan fiicnayn ay leeyihiin halista waxyar ka sareysa kansarka marka loo eego kuwa leh baaritaannada isku dhafan ee taban, iyo kuwa leh natiijooyinka xun ee HPV ee baaritaanka labaad ee la isku daray ayaa sii yareeyay halista saddexaad Markii labaad diidmo, asal ahaan waa la waayey. Soo ogaanshaha nabarrada CIN3, faa'iidooyinka baaritaanka isku dhafan ee baaritaanka HPV aad ayey u yar yihiin. Tijaabinta wadajirka ah waxay kaliya ku dartay colposcopy aan loo baahnayn iyo biopsy iyo daaweyn ka badan.
